• News
  • SAN DIEGO
  • BioTech

Ligand licenses five programs to Viking Therapeutics

San Diego-based Ligand Pharmaceuticals Inc. (Nasdaq: LGND) announced the licensing of rights to five programs to Viking Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments
Subscribe Today!